(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 September 2025 (11.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/189127 A8

(51) International Patent Classification:
A61K 31/395 (2006.01) *C07D 307/77* (2006.01)
C07D 307/82 (2006.01) *A61K 31/33* (2006.01)
C07D 307/78 (2006.01)

(21) International Application Number:
PCT/US2025/018970

(22) International Filing Date:
07 March 2025 (07.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/563,122 08 March 2024 (08.03.2024) US

(71) Applicant: **AUTOMERA PTE. LTD** [SG/SG]; 79 Science Park Drive #04-05, CINTECH IV, Singapore Science Park 1, Singapore 118264 (SG).

(72) Inventors: **NG, Shuyi Pearly**; c/o AUTOMERA PTE. LTD, 79 Science Park Drive #04-05, CINTECH IV, Singapore Science Park 1, Singapore 118264 (SG). **AHMED, Mohammed Mahmood**; c/o AUTOMERA PTE. LTD, 79 Science Park Drive #04-05, CINTECH IV, Singapore Science Park 1, Singapore 118264 (SG). **HOON, Shawn Siang**; c/o AUTOMERA PTE. LTD, 79 Science Park Drive #04-05, CINTECH IV, Singapore Science Park 1, Singapore 118264 (SG). **YAP, Kenrick An Fu**; c/o AUTOMERA PTE. LTD, 79 Science Park Drive #04-05, CINTECH IV, Singapore Science Park 1, Singapore 118264 (SG).

(74) Agent: **LAHERTY, Carol** et al.; COOLEY LLP, Attn: IP Docketing Department, 1299 Pennsylvania Avenue NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

(54) Title: BENZOFURAN DERIVATIVES FOR TARGETING AUTOPHAGY





FIG. 2A



(57) Abstract: Provided herein are compounds of formula (I), (II), and (III), or pharmaceutically acceptable salts, stereoisomers, or deuterated forms thereof, wherein X^1, X^2,X^3, R^1, R^2, a, b, L^0, L^1, L^2, and A are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of formula (I), (II), or (III), or pharmaceutically acceptable salt, a stereoisomer, or deuterated form thereof, and methods of using a compound of formula (I), (II), or (III), or pharmaceutically acceptable salt, a stereoisomer, or deuterated form thereof, e.g., in the treatment of a disease or disorder by modulating autophagic degradation and/or p62 activity.

WO 2025/189127 A8

[Continued on next page]

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

(48) **Date of publication of this corrected version:**
02 October 2025 (02.10.2025)

(15) **Information about Correction:**
see Notice of 02 October 2025 (02.10.2025)